Jeffrey Szer
Overview
Explore the profile of Jeffrey Szer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1785
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patriquin C, Bogdanovic A, Griffin M, Kelly R, Maciejewski J, Mulherin B, et al.
Adv Ther
. 2024 Apr;
41(5):2050-2069.
PMID: 38573482
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease characterized by complement-mediated hemolysis and thrombosis. Pegcetacoplan, the first targeted complement component 3 (C3) PNH therapy, was safe and efficacious...
2.
Goncalves I, Lewis C, Grainger B, Dring R, Lee N, Pasricha S, et al.
Res Pract Thromb Haemost
. 2024 Mar;
8(1):102342.
PMID: 38444612
Background: There is evidence that patients with immune thrombocytopenia (ITP) are at increased risk of thrombosis. However, the association of clinical- and treatment-related factors with thrombosis remains controversial. Objectives: To...
3.
Oran B, Ahn K, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, et al.
Transplant Cell Ther
. 2021 Aug;
27(11):921.e1-921.e10.
PMID: 34403791
Reduced-intensity conditioning (RIC) regimens developed to extend the use of allogeneic hematopoietic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the 2...
4.
Weinkove R, McQuilten Z, Adler J, Agar M, Blyth E, Cheng A, et al.
Med J Aust
. 2020 May;
212(10):481-489.
PMID: 32401360
Introduction: A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated...
5.
Schmidt S, Liu Y, Hu Z, Williams K, Lazarus H, Vij R, et al.
Biol Blood Marrow Transplant
. 2020 Feb;
26(6):1137-1143.
PMID: 32062061
Treatment for relapse of chronic myeloid leukemia (CML) following hematopoietic cell transplantation (HCT) includes tyrosine kinase inhibitors (TKIs) with or without donor lymphocyte infusions (DLIs), but the most effective treatment...
6.
DeFilipp Z, Ancheta R, Liu Y, Hu Z, Gale R, Snyder D, et al.
Biol Blood Marrow Transplant
. 2019 Nov;
26(3):472-479.
PMID: 31669399
It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia...
7.
Pasquini M, Srivastava A, Ahmed S, Aljurf M, Atsuta Y, Doleysh C, et al.
Hematol Oncol Stem Cell Ther
. 2019 Aug;
13(3):131-142.
PMID: 31449780
Hematopoietic cell transplantation (HCT) is a highly complex procedure that requires a dedicated multidisciplinary team to optimize its safety. In addition, institutions may have different needs regarding indications based on...
8.
Pasquini M, Srivastava A, Ahmed S, Aljurf M, Atsuta Y, Doleysh C, et al.
Biol Blood Marrow Transplant
. 2019 May;
25(12):2322-2329.
PMID: 31071457
Hematopoietic cell transplantation (HCT) is a highly complex procedure that requires a dedicated multidisciplinary team to optimize safety. In addition, institutions may have different needs regarding indications based on regional...
9.
Mehta R, Holtan S, Wang T, Hemmer M, Spellman S, Arora M, et al.
Blood Adv
. 2019 May;
3(9):1441-1449.
PMID: 31053571
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free...
10.
Prokopishyn N, Logan B, Kiefer D, Sees J, Chitphakdithai P, Ahmed I, et al.
Biol Blood Marrow Transplant
. 2019 Feb;
25(7):1325-1330.
PMID: 30716454
Bone marrow (BM) is an essential source of hematopoietic stem cell grafts for many allogeneic hematopoietic cell transplant (HCT) recipients, including adult patients (for specific diseases and transplantation strategies) and...